Perspectives on the Promise of Novel Agents for the Treatment of Newly Diagnosed Intermediate/High-Risk MDS
Speakers: Naval Daver, MD, Associate ProfessorGuillermo Garcia-Manero, MD, Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia
Duration: 60 minutes
Presented on: June 3, 2022
Naval Daver, MD
Naval Daver, MD
Associate ProfessorNaval Daver, MD, is an associate professor and director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease and is principal investigator on more than 25 ongoing national and international clinical trials in these diseases, including multiple registration and label enabling trials. Dr. Daver is very interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML. Furthermore, he serves as Chair on numerous national and international meetings and educational platforms.
Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD
Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of LeukemiaGuillermo Garcia-Manero, MD, is the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC). He also serves as the Chief of the Section of Myelodysplastic Syndromes and Vice Chairman of the Department of Leukemia at UT MDACC. Moreover, he serves as Leader of the MDS/AML Moon Shot Program and Program Director of the Leukemia Fellowship Program at MD Anderson Cancer Center. Dr. Garcia-Manero’s research focuses on understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for patients with these disorders. He has co- authored over 800 manuscripts. Currently, he is PI or Co-PI on over 30 active clinical trials focusing on AML and MDS.
CME InformationPerspectives on the Promise of Novel Agents for the Treatment of Newly Diagnosed Intermediate/High-Risk MDSThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Aplastic Anemia and MDS International Foundation (AAMDSIF).
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Gilead Sciences, Inc.
DATE OF RELEASE/EXPIRATIONThis activity was released on June 3, 2022 and is valid for 12 months. Requests for credit must be made no later than June 3, 2023.
TARGET AUDIENCEThe educational design of this activity addresses the needs of hematologic oncologists, hematologists, medical oncologists, BMT specialists, NPs, PAs, oncology nurses, and other clinicians involved in the management of patients with MDS.
STATEMENT OF NEED/PROGRAM OVERVIEWWhile current therapies are inadequate for many patients with myelodysplastic syndromes (MDS), emerging therapies with different mechanisms of action are poised to provide more treatment options for newly diagnosed MDS and allow clinicians to treat with more certainty.
Join Dr. Naval Daver and Dr. Guillermo Garcia-Manero from MD Anderson Cancer Center to discuss current treatment options and unmet needs for different patient populations with MDS. The expert panel will further explore emerging targeted and combination therapies, including rationale for use, novel mechanisms of action, and the latest clinical data. As an issue of great importance, the evidence on disparities in clinical trials will be reviewed and strategies shared to educate patients on the clinical-trial process and its benefits, while encouraging enrollment when appropriate. Patient interviews will ensure the education remains patient-focused by providing their experiences with treatment and the clinical decision-making process.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Discuss the rationale for and mechanisms of action of novel agents under investigation for newly diagnosed MDS
- Evaluate efficacy and safety data from latest clinical trials on emerging novel agents for newly diagnosed MDS
- Recognize disparities in clinical trials and implement methods to reduce barriers by counseling eligible patients to participate in clinical trials
- Identify patient-centered approaches to MDS care via real-world patient accounts
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians..
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATIONGlobal Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Nothing to disclose Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Consulting Fee (e.g., Advisory Board): AbbVie, Agios, Amgen, Arog, Astellas, Bristol-Meyers Squibb, Celgene, Daichii-Sankyo, Genentech, Gilead, ImmunoGen, Jazz, Novartis, Pfizer, Servier Shattuck Labs, Syndax, Trillium
Contracted Research: AbbVie, Amgen, Astellas, Bristol-Meyers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, Novimmune, Pfizer, Servier, Trillium, Trovagene
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner Reported Financial Relationship Rhys Williams, MSN, FNP-C, RN Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Jaimee Harris-Gold Nothing to disclose Tariqa Ackbarali Nothing to disclose Dan Stowell – Patient Participant Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com
Technical Support:For any technical issues or issues with your CME Certificate, please contact OMedLive.com at 877-394-1306 or at Support@OMedLive.com.